Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Phase 2

Terminated

Conditions: Primary Central Nervous System Lymphoma

Interventions: Drug: Rituximab plus Temozolomide

First Posted Date: 2014-04-14

Last Posted Date: 2017-02-07

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 2

Registration Number: NCT02113007

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Memorial Cancer Institute, Hollywood, Florida, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States

and more 1 locations

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Phase 2

Withdrawn

Conditions: Advanced Prostate Cancer

Interventions: Drug: BKM 120
Drug: Cabazitaxel

First Posted Date: 2014-01-14

Last Posted Date: 2016-02-11

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02035124

Locations: 🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Orteronel

First Posted Date: 2013-11-21

Last Posted Date: 2022-06-30

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 71

Registration Number: NCT01990209

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Hope Cancer Center, Terre Haute, Indiana, United States

and more 5 locations

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Phase 2

Terminated

Conditions: Metastatic Breast Cancer With Intracranial Metastases

Interventions: Drug: cabazitaxel
Drug: lapatinib

First Posted Date: 2013-09-04

Last Posted Date: 2017-07-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 11

Registration Number: NCT01934894

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
🇺🇸
Oncology Hematology Care Inc., Cincinnati, Ohio, United States

and more 1 locations

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
T-cell Lymphoma
Lymphoma

Interventions: Drug: IPI-145
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2013-06-07

Last Posted Date: 2016-07-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 48

Registration Number: NCT01871675

Locations: 🇺🇸
The Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Oklahoma University, Oklahoma City, Oklahoma, United States

and more 1 locations

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Ofatumumab

First Posted Date: 2013-05-07

Last Posted Date: 2017-06-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 34

Registration Number: NCT01848145

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists-South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States

and more 3 locations

Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: OGX-427
Drug: Placebo

First Posted Date: 2013-05-01

Last Posted Date: 2017-05-16

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 132

Registration Number: NCT01844817

Locations: 🇺🇸
University of California-San Francisco, San Francisco, California, United States
🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States

and more 8 locations

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Non Squamous Non Small Cell Lung Cancer

Interventions: Drug: OGX-427
Drug: Placebo

First Posted Date: 2013-04-11

Last Posted Date: 2018-06-08

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 155

Registration Number: NCT01829113

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists-South, Fort Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States

and more 13 locations

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

Phase 2

Terminated

Conditions: HER2 Positive Esophagogastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Drug: Lapatinib
Radiation: Radiation Therapy

First Posted Date: 2013-01-16

Last Posted Date: 2016-06-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 12

Registration Number: NCT01769508

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States

and more 6 locations

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Radiation: Radiation
Drug: Aflibercept
Procedure: Surgery
Drug: FOLFOX6

First Posted Date: 2012-12-17

Last Posted Date: 2017-02-07

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 39

Registration Number: NCT01749956

Locations: 🇺🇸
Florida Cancer Specialists, St. Petersburg, Florida, United States
🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸
Space Coast Cancer Center, Titusville, Florida, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy